Answers are grounded in this paper and cite their sources.
Laboratory tests show Caulis polygoni multiflori enhances antibacterial effects against Staphylococcus aureus, suggesting potential for combination therapy.
Staphylococcus aureus (SA), particularly methicillin-resistant Staphylococcus aureus (MRSA), represents a major clinical challenge due to its ability to form biofilms, which contribute to treatment failure and recurrent infections. This study evaluated the antibacterial and anti-biofilm activity of the water extract of Caulis Polygoni Multiflori (CPM) against clinical and standard strains of SA. CPM exhibited consistent bacteriostatic and bactericidal effects, with time-kill assays confirming rapid elimination of planktonic bacteria at 2×MIC. Mechanistically, CPM dose-dependently inhibited bacterial adhesion to fibrin and suppressed biofilm formation, though it did not disrupt pre-formed biofilms, likely due to poor penetration into the biofilm matrix. In combination studies, CPM showed clear synergistic or additive effects with erythromycin in broth microdilution assays, but not in disk diffusion tests, possibly reflecting limited diffusion of CPM components in solid media. Importantly, CPM’s activity was independent of bacterial resistance profiles. These findings indicate that CPM acts through both direct bactericidal activity and anti-virulence mechanisms, and represents a promising candidate for topical combination therapy against MRSA skin and wound infections. Further studies are needed to elucidate its molecular mechanisms.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: